Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more
Jubilant Pharmova Limited (JUBLPHARMA) - Net Assets
Latest net assets as of September 2025: ₹65.72 Billion INR
Based on the latest financial reports, Jubilant Pharmova Limited (JUBLPHARMA) has net assets worth ₹65.72 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹135.21 Billion) and total liabilities (₹69.50 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹65.72 Billion |
| % of Total Assets | 48.6% |
| Annual Growth Rate | 17.53% |
| 5-Year Change | 31.57% |
| 10-Year Change | 114.42% |
| Growth Volatility | 34.31 |
Jubilant Pharmova Limited - Net Assets Trend (2004–2025)
This chart illustrates how Jubilant Pharmova Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jubilant Pharmova Limited (2004–2025)
The table below shows the annual net assets of Jubilant Pharmova Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹62.39 Billion | +15.08% |
| 2024-03-31 | ₹54.21 Billion | +0.54% |
| 2023-03-31 | ₹53.92 Billion | +1.42% |
| 2022-03-31 | ₹53.16 Billion | +12.12% |
| 2021-03-31 | ₹47.42 Billion | -15.39% |
| 2020-03-31 | ₹56.04 Billion | +16.53% |
| 2019-03-31 | ₹48.09 Billion | +19.18% |
| 2018-03-31 | ₹40.35 Billion | +18.79% |
| 2017-03-31 | ₹33.97 Billion | +16.74% |
| 2016-03-31 | ₹29.10 Billion | +18.59% |
| 2015-03-31 | ₹24.54 Billion | -11.89% |
| 2014-03-31 | ₹27.84 Billion | +6.85% |
| 2013-03-31 | ₹26.06 Billion | +8.64% |
| 2012-03-31 | ₹23.99 Billion | +8.34% |
| 2011-03-31 | ₹22.14 Billion | -1.12% |
| 2010-03-31 | ₹22.39 Billion | +76.66% |
| 2009-03-31 | ₹12.68 Billion | +0.90% |
| 2008-03-31 | ₹12.56 Billion | +38.63% |
| 2007-03-31 | ₹9.06 Billion | +7.77% |
| 2006-03-31 | ₹8.41 Billion | +66.66% |
| 2005-03-31 | ₹5.04 Billion | +140.46% |
| 2004-03-31 | ₹2.10 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jubilant Pharmova Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4957.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹53.02 Billion | 84.76% |
| Common Stock | ₹158.00 Million | 0.25% |
| Other Comprehensive Income | ₹9.37 Billion | 14.99% |
| Total Equity | ₹62.55 Billion | 100.00% |
Jubilant Pharmova Limited Competitors by Market Cap
The table below lists competitors of Jubilant Pharmova Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hatsun Agro Product Limited
NSE:HATSUN
|
$614.52 Million |
|
Poseida Therapeutics Inc
NASDAQ:PSTX
|
$614.61 Million |
|
Voltamp Transformers Limited
NSE:VOLTAMP
|
$614.78 Million |
|
Wuxi ETEK Microelectronics Co Ltd
SHG:688601
|
$614.92 Million |
|
MORGAN ADVANCED MAT.LS-25
F:MGJ
|
$614.42 Million |
|
BIEM.L .FDLKK Garment Co Ltd
SHE:002832
|
$614.30 Million |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
$614.30 Million |
|
Haian Rubber Grp Co Ltd
SHE:001233
|
$613.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jubilant Pharmova Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 54,339,000,000 to 62,549,000,000, a change of 8,210,000,000 (15.1%).
- Net income of 8,394,000,000 contributed positively to equity growth.
- Dividend payments of 796,000,000 reduced retained earnings.
- Share repurchases of 56,000,000 reduced equity.
- New share issuances of 9,000,000 increased equity.
- Other comprehensive income increased equity by 589,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹8.39 Billion | +13.42% |
| Dividends Paid | ₹796.00 Million | -1.27% |
| Share Repurchases | ₹56.00 Million | -0.09% |
| Share Issuances | ₹9.00 Million | +0.01% |
| Other Comprehensive Income | ₹589.00 Million | +0.94% |
| Other Changes | ₹70.00 Million | +0.11% |
| Total Change | ₹- | 15.11% |
Book Value vs Market Value Analysis
This analysis compares Jubilant Pharmova Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 64.74x to 2.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹12.94 | ₹837.70 | x |
| 2005-03-31 | ₹31.39 | ₹837.70 | x |
| 2006-03-31 | ₹51.89 | ₹837.70 | x |
| 2007-03-31 | ₹55.85 | ₹837.70 | x |
| 2008-03-31 | ₹77.60 | ₹837.70 | x |
| 2009-03-31 | ₹77.65 | ₹837.70 | x |
| 2010-03-31 | ₹138.34 | ₹837.70 | x |
| 2011-03-31 | ₹136.51 | ₹837.70 | x |
| 2012-03-31 | ₹146.27 | ₹837.70 | x |
| 2013-03-31 | ₹156.60 | ₹837.70 | x |
| 2014-03-31 | ₹164.90 | ₹837.70 | x |
| 2015-03-31 | ₹154.04 | ₹837.70 | x |
| 2016-03-31 | ₹186.24 | ₹837.70 | x |
| 2017-03-31 | ₹220.32 | ₹837.70 | x |
| 2018-03-31 | ₹262.22 | ₹837.70 | x |
| 2019-03-31 | ₹308.53 | ₹837.70 | x |
| 2020-03-31 | ₹351.83 | ₹837.70 | x |
| 2021-03-31 | ₹297.71 | ₹837.70 | x |
| 2022-03-31 | ₹334.14 | ₹837.70 | x |
| 2023-03-31 | ₹339.26 | ₹837.70 | x |
| 2024-03-31 | ₹342.06 | ₹837.70 | x |
| 2025-03-31 | ₹393.71 | ₹837.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jubilant Pharmova Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.42%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.60%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 2.04x
- Recent ROE (13.42%) is below the historical average (13.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 38.00% | 9.11% | 0.99x | 4.22x | ₹576.48 Million |
| 2005 | 23.87% | 10.19% | 0.93x | 2.53x | ₹692.49 Million |
| 2006 | 15.70% | 8.61% | 0.73x | 2.48x | ₹471.03 Million |
| 2007 | 25.65% | 12.60% | 0.56x | 3.65x | ₹1.39 Billion |
| 2008 | 32.43% | 16.09% | 0.59x | 3.41x | ₹2.77 Billion |
| 2009 | 22.92% | 8.05% | 0.53x | 5.34x | ₹1.60 Billion |
| 2010 | 19.15% | 11.15% | 0.55x | 3.10x | ₹2.01 Billion |
| 2011 | 10.58% | 6.69% | 0.45x | 3.48x | ₹124.92 Million |
| 2012 | 0.62% | 0.34% | 0.55x | 3.37x | ₹-2.18 Billion |
| 2013 | 6.12% | 2.96% | 0.61x | 3.38x | ₹-967.08 Million |
| 2014 | -2.20% | -0.99% | 0.66x | 3.37x | ₹-3.20 Billion |
| 2015 | -2.35% | -0.99% | 0.67x | 3.52x | ₹-3.03 Billion |
| 2016 | 13.47% | 6.82% | 0.64x | 3.08x | ₹1.01 Billion |
| 2017 | 16.75% | 9.82% | 0.65x | 2.63x | ₹2.32 Billion |
| 2018 | 15.73% | 8.55% | 0.78x | 2.35x | ₹2.34 Billion |
| 2019 | 11.95% | 6.31% | 0.79x | 2.38x | ₹935.64 Million |
| 2020 | 16.03% | 15.03% | 0.48x | 2.23x | ₹3.38 Billion |
| 2021 | 17.63% | 13.71% | 0.68x | 1.88x | ₹3.62 Billion |
| 2022 | 7.78% | 6.75% | 0.61x | 1.88x | ₹-1.18 Billion |
| 2023 | -1.13% | -0.97% | 0.56x | 2.07x | ₹-6.01 Billion |
| 2024 | 1.42% | 1.15% | 0.58x | 2.13x | ₹-4.66 Billion |
| 2025 | 13.42% | 11.60% | 0.57x | 2.04x | ₹2.14 Billion |
Industry Comparison
This section compares Jubilant Pharmova Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jubilant Pharmova Limited (JUBLPHARMA) | ₹65.72 Billion | 38.00% | 1.06x | $614.47 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |